Here, the authors show that Msx2 deficiency prevents osteoclast fusion and enhances type H vessel- mediated osteogenesis. Mechanically, MSX2 protects PU.1 from FBXW7 mediated degradation and targeting Msx2 serves as an anabolic therapy in pre-clinical models of osteoporosis.
- Qingliang Ma
- Shiyu Wang
- Zhiwei Jie
